Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q4 2021 Results Conference Call April 27, 2022 03:30 AM ET Company Participants Hiroyuki Okuzawa - Head of Corporate Planning & Management.
AstraZeneca and Daiichi Sankyo's Enhertu posted a first-in-class win in HER2-low breast cancer. Takeda signed a deal worth up to $2 billion to develop non-viral gene therapies. U.S. lawmakers lent support to a march-in petition asking the government to sidestep patents protecting Astellas and Pfizer's Xtandi. And more.